125 related articles for article (PubMed ID: 28223669)
1. [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
Kida K; Murai M; Yamauchi H
Gan To Kagaku Ryoho; 2017 Feb; 44(2):111-115. PubMed ID: 28223669
[TBL] [Abstract][Full Text] [Related]
2. [Molecular Diagnosis and Treatment of HBOC Syndrome].
Miki Y
Gan To Kagaku Ryoho; 2017 Feb; 44(2):102-106. PubMed ID: 28223667
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
5. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
6. Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
Casey MJ; Colanta AB
Fam Cancer; 2016 Jul; 15(3):371-84. PubMed ID: 26875157
[TBL] [Abstract][Full Text] [Related]
7. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
[TBL] [Abstract][Full Text] [Related]
9. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
11. Surgical Management of Hereditary Breast Cancer.
Berger ER; Golshan M
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573353
[TBL] [Abstract][Full Text] [Related]
12. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoprevention for hereditary breast and ovarian cancer.
Cazzaniga M; Bonanni B
Minerva Ginecol; 2016 Oct; 68(5):517-35. PubMed ID: 26928419
[TBL] [Abstract][Full Text] [Related]
14. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
15. Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
Singer CF
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32989958
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Management of HBOC in Our Hospital].
Nomura H; Takeshima N
Gan To Kagaku Ryoho; 2017 Feb; 44(2):116-120. PubMed ID: 28223670
[TBL] [Abstract][Full Text] [Related]
17. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Yoshida R
Breast Cancer; 2021 Nov; 28(6):1167-1180. PubMed ID: 32862296
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
19. Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium.
Nakamura S; Kwong A; Kim SW; Iau P; Patmasiriwat P; Dofitas R; Aryandono T; Hu Z; Huang CS; Ginsburg O; Rashid MU; Sarin R; Teo SH
Public Health Genomics; 2016; 19(1):53-60. PubMed ID: 26575363
[TBL] [Abstract][Full Text] [Related]
20. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
